VibroSense wins Japan patent for chemotherapy-induced neuropathy biomarker

Reuters2026/08/14 06:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

VibroSense Dynamics received a Japan patent on April 21, 2026, covering a biomarker to predict chemotherapy-induced peripheral neuropathy risk.
The patent mirrors protection previously granted by the European Patent Office, strengthening the company’s intellectual property position in CIPN.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VibroSense Dynamics AB published the original content used to generate this news brief via Cision (Ref. ID: 202608140230BITN____UKPR__SV_20260731-BIT-3422-0) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

VibroSense wins Japan patent for chemotherapy-induced neuropathy biomarker

You may also like

Crypto prices